A needle-free nasal adrenaline spray for emergency anaphylaxis treatment is now available for prescription in the UK.

The EURneffy® 2mg nasal adrenaline spray, which is portable and ready-to-use in emergencies is the UK’s first needle-free emergency anaphylaxis treatment for adults and children (≥30 kg) with life-threatening allergies.¹

The spray offers a new pocket-sized alternative to adrenaline auto-injectors (AAIs) for people living with severe allergies, including those with needle phobias or who need a more convenient option that they can rely on. EURneffy® has a longer shelf life and can withstand temperature changes better than AAIs,^1,2 which has the potential to result in cost savings per day for the NHS.³

EURneffy® is a non-invasive treatment option that provides rapid absorption of adrenaline through the nose.¹ Extensive clinical pharmacological data from the EURneffy® development programme, involving over 700 participants, has demonstrated the comparable effectiveness of EURneffy® 2 mg to AAIs across a broad range of patient scenarios,⁴ including when someone had cold or flu symptoms and significant nasal congestion.^1,5

In the first analysis of real-world treatment outcomes in the United States, nearly 9 in 10 patients experiencing allergic reactions were successfully treated with a single dose of EURneffy®, and only 1 in 10 required a second dose.⁶
The outcomes are very similar to historic treatment response rates reported with adrenaline injections⁷ and support the real-world clinical effectiveness of EURneffy® in anaphylaxis. 

According to new research from ALK, 88% of HCPs know patients or caregivers who have not been able to use their AAI in an emergency, even though it could have helped.⁸
HCPs think alternative adrenaline delivery methods could help treatment of anaphylaxis in the community, improving ease of use (45%), reducing anxiety (40%) and reducing hesitation in emergencies (34%).⁸

Due to differences in formulation, EURneffy® offers double the real-world shelf life of traditional AAIs (22 months and 11 months, respectively)^3,9,10 and requires no special storage conditions,¹ which could reduce the need for replacement devices by 32% per year.*³

ALK received approval for EURneffy® 2mg from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) in July 2025.¹
It is indicated for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis in adults and children who weigh 30kg or more.¹ As with all adrenaline devices, it is recommended that two EURneffy® devices are carried to treat a potentially life-threatening emergency in case a second dose is required.¹ 

Dr Shuaib Nasser, Consultant Allergist and Respiratory Physician and Clinical Lead for Allergy at Cambridge University Hospital NHS foundation Trust, said: “With EURneffy® now available for prescription, we can offer an alternative, needle-free method of adrenaline delivery that may be easier for patients and families to manage and administer. The ready-to-use and portable design may help address some of the practical and psychological barriers to consistently carrying and using adrenaline auto-injectors, especially needle anxiety. The pharmacological data show that EURneffy® achieves outcomes comparable to adrenaline auto-injectors, regardless of nasal congestion, leading to its approval here in the UK. What’s exciting is that we’re now also seeing the first real-world evidence, which should provide further assurance to prescribers of its interchangeability with adrenaline injection.”

*based on internal modelling

References